Save Product
Product Details
Materials Provided
IDComponentsSizeEP162-C01High-bind Plate1 plateEP162-C02Human OX40 Ligand10 μgEP162-C03Biotinylated Human OX4010 μgEP162-C04Anti-OX40 Neutralizing Antibody10 μgEP162-C05Streptavidin-HRP5 μgEP162-C06Coating Buffer12 mLEP162-C0720xWashing Buffer50 mLEP162-C08Blocking Buffer50 mLEP162-C09Substrate Solution12 mLEP162-C10Stop Solution7 mLProduct Overview
OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human OX40 binding to human OX40 Ligand. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human OX40 binding to human OX40 Ligand.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.
INHIBITION OF OX40[Biotinylated]: OX40 Ligand BINDING BY ANTI-OX40 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-OX40 Neutralizing antibody (Catalog # EP162-C04) (1:1 serial dilution, from 0.5 μg/mL to 0.0078125 μg/mL) was added into OX40[Biotinylated]: OX40 Ligand binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor receptor superfamily member 4
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
28 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing